Abstracts Archive - Page 812 of 2425 - ACR Meeting Abstracts

Abstract Number: 804 • 2019 ACR/ARP Annual Meeting
STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis
Jose Luis Tandaipan¹, Mireia Lopez Corbeto ² and Estefania Moreno Ruzafa ³, ¹Hospital Universitari Mutua Terrassa, Terrassa, Spain, ²Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, ³Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: Gain-of-function mutations in TMEM173 encoding STING (Stimulator of Interferon Genes) underlie a novel type I INF termed SAVI syndrome. It is characterized by a…
Abstract Number: 805 • 2019 ACR/ARP Annual Meeting
Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
Shivani Garg¹, Christie Bartels ¹, Cristina Drenkard ², Gaobin Bao ² and S Sam Lim ², ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Emory University, Atlanta, GA
Background/Purpose: SLE is an independent risk factor for premature cardiovascular disease (CVD) and afflicts African Americans (AA’s) 3 times more than whites. Two predominantly white…
Abstract Number: 806 • 2019 ACR/ARP Annual Meeting
A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne ² and Peter Merkel ³, ¹University of Cambridge, Cambridge, England, United Kingdom, ²Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and relapse rates…
Abstract Number: 807 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Atul Deodhar¹, Philip Helliwell ², Wolf-Henning Boencke ³, Elizabeth Hsia ⁴, Alexa Kollmeier ⁵, Ramanand Subramanian ⁵, Xie Xu ⁵, Shihong Sheng ⁵, Bei Zhou ⁵ and Christopher Ritchlin ⁶, ¹Oregon Health & Science University, Portland, OR, ²University of Leeds, Leeds, United Kingdom, ³Geneva Univ Hospitals, Geneva, Switzerland, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved to treat PsO. We evaluated GUS efficacy and safety in a Phase 3, double-blind, PBO-controlled trial…
Abstract Number: 808 • 2019 ACR/ARP Annual Meeting
Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial
John Stone¹, Min Bao ², Jian Han ², Martin Aringer ³, Daniel Blockmans ⁴, Elisabeth Brouwer ⁵, Maria C. Cid ⁶, Bhaskar Dasgupta ⁷, Jürgen Rech ⁸, Carlo Salvarani ⁹, Robert Spiera ¹⁰ and Sebastian Unizony ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA, ³Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁴Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Hospital for Special Surgery, New York, NY
Background/Purpose: Tocilizumab (TCZ) 162 mg administered subcutaneously weekly (QW) or every-other-week (Q2W) plus 26-wk prednisone tapering resulted in higher rates of sustained glucocorticoid (GC)–free remission…
Abstract Number: 809 • 2019 ACR/ARP Annual Meeting
TNF-α Drives Progressive Obliterative Pulmonary Vascular Disease and Represents a Novel Model of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH)
Benjamin Korman¹, Richard Bell ¹, R James White ², Maria de la luz Garcia-Hernandez ³, Emily Wu ², Pamela Slattery ², Nelson Huertas ², Stacey Duemmel ², Marc Nuzzo ², Homaira Rahimi ⁴, Craig Morrell ², Christopher Ritchlin ³ and Edward Schwarz ², ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester, Rochester, NY, ³Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ⁴University of Rochester Medical Center, Rochester
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary disease characterized by an obliterative vasculopathy and vascular remodeling, right heart hypertrophy, and premature death. Connective…
Abstract Number: 810 • 2019 ACR/ARP Annual Meeting
Small Vessel Vasculitis Syndrome with Autoinflammation Caused by De Novo Mutations in LYN Kinase
Adriana de Jesus¹, Gina Montealegre Sanchez ², Helen Freeman ³, Neil Martin ⁴, Ebun Omoyinmi ⁵, Katherine Calvo ⁶, Richard Chyi-chia Lee ⁷, Murray Passo ⁸, Natasha Ruth ⁸, David Kleiner ⁷, Yan Huang ⁹, Nirali Shah ¹⁰, Paul Brogan ¹¹, SuJin Hwang ¹², HyeSun Kuehn ¹², Sergio Rosenzweig ¹², Zuoming Deng ¹³, Anna Huttenlocher ¹⁴, Susan Moir ¹⁵, Douglas Kuhns ¹⁶ and Raphaela Goldbach-Mansky ¹⁷, ¹Translation Autoinflammatory Diseases Section/NIAID/NIH, Silver Spring, MD, ²Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, ³Raigmore Hospital, Inverness, United Kingdom, ⁴Royal Hospital for Children, Glasgow, United Kingdom, ⁵University College London Institute of Child Health, London, United Kingdom, ⁶Hematology Service/Department of Laboratory Medicine/NIH, Bethesda, MD, ⁷Laboratory of Pathology/NCI/NIH, Bethesda, MD, ⁸Medical University of South Carolina, Charleston, SC, ⁹Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, MD, ¹⁰Pediatric Oncology Branch/NCI/NIH, Bethesda, MD, ¹¹Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ¹²Immunology Service/Department of Laboratory Medicine/NIH, Bethesda, MD, ¹³Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ¹⁴Department of Pediatrics/University of Wisconsin, Madison, WI, ¹⁵Immunopathogenesis Section/NIAID/NIH, Bethesda, MD, ¹⁶Collaborative Clinical Research Branch/NIAID/NIH, Bethesda, MD, ¹⁷Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, MD
Background/Purpose: Lyn kinase is a member of the Src family of non-receptor tyrosine-protein kinases that modifies signals from various cell surface receptors and regulates innate…
Abstract Number: 811 • 2019 ACR/ARP Annual Meeting
Monomethyl Fumarate as a Novel Therapy for Macrophage Activation Syndrome: Mechanism of Action in an Animal Model
Chhanda Biswas ¹, Thomas Burn ¹, Niansheng Chu ¹ and Edward Behrens¹, ¹The Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Macrophage activation syndrome (MAS) is a deadly systemic inflammatory condition marked by an increase in enzymes of iron metabolism including ferritin and heme-oxygenase 1…
Abstract Number: 812 • 2019 ACR/ARP Annual Meeting
Sex Differences in Autoimmunity and Cardiovascular Risk Could Be Associated with Altered Treg Phenotype and Lipoprotein Metabolism
George Robinson¹, Kirsty Waddington ¹, Anna Radziszewska ¹, Hannah Peckham ¹, David A Isenberg ², Yiannis Ioannou ¹, Coziana Ciurtin ³, Ines Pineda-Torra ¹ and Elizabeth Jury ¹, ¹University College London, London, United Kingdom, ²Centre for Rheumatology, London, United Kingdom, ³Centre for Adolescent Rheumatology, University College London London, UK, Londond, United Kingdom
Background/Purpose: Males and females have altered immune responses resulting in variation in autoimmune risk. Sex differences exist in the frequency and activity of immune-cell subsets…
Abstract Number: 813 • 2019 ACR/ARP Annual Meeting
Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome
Grant Schulert¹, Thuy Do ¹, Sanjeev Dhakal ¹, Ndate Fall ², Mario Medvedovich ³, Sherry Thornton ¹, Nathan salomonis ² and Alexei A. Grom ¹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe and distinct subtype of childhood arthritis. Children with SJIA are at risk for macrophage activation syndrome…
Abstract Number: 814 • 2019 ACR/ARP Annual Meeting
Interferon Signature and Cytokine Patterns Define Novel Autoinflammatory Diseases
Adriana de Jesus¹, Yangfeng Hou ², Stephen Brooks ³, Louise Malle ⁴, Angelique Biancotto ⁵, Yan Huang ⁶, Katherine Calvo ⁷, Bernadette Marrero ⁸, Susan Moir ⁹, Andrew Oler ¹⁰, Zuoming Deng ³, Gina Montealegre Sanchez ¹, Scott Canna ¹¹ and Raphaela Goldbach-Mansky ¹², ¹Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, ²Department of Rheumatology, Shandong Provincial Qianfoshan Hospital, Shandong University, Shandong, China (People's Republic), ³Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ⁴Translational Autoinflammatory Diseases Section (TADS), NIAID/NIH, Bethesda, ⁵NIH/CHI, Bethesda, ⁶Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, MD, ⁷Hematology Service/Department of Laboratory Medicine/NIH, Bethesda, MD, ⁸Computational Systems Biology Section/NIAID/NIH, Bethesda, ⁹Immunopathogenesis Section/NIAID/NIH, Bethesda, MD, ¹⁰NIH/NIAID, Bethesda, ¹¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, ¹²Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, MD
Background/Purpose: Undifferentiated systemic autoinflammatory diseases (USAID) present diagnostic and therapeutic challenges. Cytokine dysregulation may identify disease groups that respond to targeted treatments. IFN-signaling blocking treatments…
Abstract Number: 815 • 2019 ACR/ARP Annual Meeting
Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis
Koji Fukuda¹, Yasushi Miura ², Shinya Hayashi ¹, Toshihisa Maeda ³ and Ryosuke Kuroda ¹, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Division of Orthopedic Science, Department Of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Matsubara Mayflower Hospital, Kobe, Japan
Background/Purpose: Fas ligand (FasL) is a member of tumor necrosis factor superfamily (TNFSF6) and reported to contribute to synovial hyperplasia of rheumatoid arthritis (RA). Apoptosis…
Abstract Number: 816 • 2019 ACR/ARP Annual Meeting
The Long Non-coding RNA HOTAIR Regulates BMP2 and Wnt Pathways in Synovial Fibroblasts
Muriel Elhai¹, Raphael Micheroli ¹, Mojca Frank-Bertoncelj ², Kerstin Klein ¹, Oliver Distler ³ and Caroline Ospelt ², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland., Zürich, Switzerland, ²University Hospital Zürich, Zürich, Switzerland, ³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Mechanisms involved in joint patterning of rheumatic diseases remain unknown. The long non-coding RNA HOTAIR is exclusively expressed in synovial fibroblasts (SF) from lower…
Abstract Number: 817 • 2019 ACR/ARP Annual Meeting
Enhanced Expression of mRNA for TAK1 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Shunsei Hirohata¹, Tatsuo Nagai ², Tetsuya Tomita ³ and Hideki Yoshikawa ³, ¹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Tatsuno, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Osaka University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial hyperplasia, consisting of type A macrophage-like synoviocytes and type B fibroblast-like synoviocytes (FLS).…
Abstract Number: 818 • 2019 ACR/ARP Annual Meeting
Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis
Jerome Avouac¹, Sonia Pezet ², Eloïse Vandebeuque ¹ and Yannick Allanore ¹, ¹Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ²INSERM U1016, Paris, France
Background/Purpose: Synovial neoangiogenesis is an early and crucial event to promote the development of the hyperplasic proliferative pathologic synovium in rheumatoid arthritis (RA). A recent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].